Yes, Madam Chair.
In terms of the experience of the National Microbiology Laboratory, my own experience, and that of my scientists, who I consulted on this yesterday, we have had no difficulty accessing manufacturing capacity for high-quality clinical-grade material for vaccine in clinical trials. The biggest obstacle has been cost rather than finding a facility to do that. So I would not agree with the assessment of the witness. In my own experience, that's not the case. There are other obstacles, certainly, for an academic-based researcher to get trial lots manufactured, but having the facilities to manufacture them is not one, in my experience.